astrazeneca - Search News

AstraZeneca, breast cancer and daiichi Sankyo

AstraZeneca and Daiichi’s breast cancer drug gets EU backing

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in the U.S. and Japan.

Benzinga.com · 2d

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

MarketWatch · 3d

AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial,

Seeking Alpha on MSN · 3d

AstraZeneca's Enhertu gets additional FDA approval

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of unresectable or metastatic HR-positive,

FierceBiotech19h

AstraZeneca antibody protects macaques from severe bird flu, suggesting prophylactic potential in case of outbreak

All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

Zacks.com on MSN1d

Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

1don MSN

AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Guggenheim Sticks to Their Buy Rating for AstraZeneca (AZN)

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

BioSpace3d

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

AstraZeneca PLC ADR rises Monday, outperforms market

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

Business Facilities6d

AstraZeneca Will Invest $820M In Ontario R&D Hub

AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...

Morningstar3d

AstraZeneca PLC ADR AZN

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca rises Wednesday, outperforms market

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

‘I was desperate for the AstraZeneca vaccine to succeed. Then I became alarmed by what I saw’

Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

AstraZeneca, breast cancer and daiichi Sankyo

Related topics